Thus, the improvement in insulin sensitivity with a reduction in circulating NEFAs due to n-3 PUFA supplementation observed in our study suggests that there is a reduction in NAFLD risk factors in obese patients with high GIP levels. This evidence concerns the gene GIP and metabolic dysfunction-associated steatotic liver disease.